Front line treatment of elderly multiple myeloma in the era of novel agents. - Wikidata - awgldk - TriplyDB

Front line treatment of elderly multiple myeloma in the era of novel agents.

Front line treatment of elderly multiple myeloma in the era of novel agents.

http://www.wikidata.org/entity/Q37303213

about

Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

P2860

Q35630256-EF2DF02D-E27D-4738-BBDA-9F8727183563 Q49761601-8081910F-3B34-44FB-AADC-8B6C8F31C3D6

P2860

Front line treatment of elderly multiple myeloma in the era of novel agents.

http://www.wikidata.org/entity/Q37303213

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Front line treatment of elderly multiple myeloma in the era of novel agents.

@en

Front line treatment of elderly multiple myeloma in the era of novel agents.

@nl

type

label

Front line treatment of elderly multiple myeloma in the era of novel agents.

@en

Front line treatment of elderly multiple myeloma in the era of novel agents.

@nl

prefLabel

Front line treatment of elderly multiple myeloma in the era of novel agents.

@en

Front line treatment of elderly multiple myeloma in the era of novel agents.

@nl

P1433

Q37303213-9DC0270B-0BF3-4E88-95F0-846DC78DC913

P1476

Q37303213-627B313F-C4D1-4D81-AB30-B2B21E8D3A9D

P2093

Q37303213-1C571265-446D-491C-945D-1BBF69835839

Q37303213-2444E198-7A09-4896-8455-8FE70BA97A0B

Q37303213-386F1345-6AD7-49F8-B620-6FCC0FAE3ABF

Q37303213-7ADFF9E9-92B7-4DFD-B4DC-0E41858E31C3

Q37303213-BD62B63C-62E9-45BF-BCDF-4A7B3F7215DD

Q37303213-F4D4B9E3-BE63-4F2F-AE27-77EE723E30A4

P2860

Q37303213-042647B9-AD58-47D9-A084-80CF5952E48C

Q37303213-0EE71AF8-2C4E-47D9-AD02-309300698D50

Q37303213-10F050AE-F7D8-4CAC-AEDC-846C24F4126D

Q37303213-1402D351-CA33-4297-AED7-06BECD3D0E23

Q37303213-1785B06E-8220-4DC4-855C-BDAA6DF39375

Q37303213-18FC5801-C441-4EDB-A833-1E22D6F1E49E

Q37303213-1EB4F8D7-2AD9-4B1B-81A6-6B589FD194B7

Q37303213-26AFA619-168A-4140-B5DE-0D4F1AA0115E

Q37303213-2B3232A1-43AE-49FD-91E0-DE4B3F029903

Q37303213-3280AA74-6958-4514-AF90-FDCC36085DA4

P304

Q37303213-5A4D7379-0DEF-4BB6-8768-C94C07CD7670

P31

Q37303213-CB476BF0-94F8-465D-82BE-CE8466E6CF8A

P478

Q37303213-C186F882-68BC-4F54-BC4E-8E0E04E0D562

P50

Q37303213-6D755678-6A5A-4F71-AE44-6D0509113F87

Q37303213-C097C819-40DE-4545-83D8-15F3E84D1ECF

P577

Q37303213-1AFE778D-F2AB-4206-9C20-F04BE41AB955

P698

Q37303213-0012BDCC-44E6-405F-B8C7-D10FCD162FD3

P932

Q37303213-815AE471-1AF7-4340-B8EF-7DA8703DF156

P1433

Biologics: Targets and Therapy

P1476

Front line treatment of elderly multiple myeloma in the era of novel agents.

@en

P2093

Aldo M Roccaro

http://www.w3.org/2001/XMLSchema#string

Anne-Sophie Moreau

http://www.w3.org/2001/XMLSchema#string

Irene M Ghobrial

http://www.w3.org/2001/XMLSchema#string

Julie Gay

http://www.w3.org/2001/XMLSchema#string

Marie-Dominique Venon

http://www.w3.org/2001/XMLSchema#string

Remy Dulery

http://www.w3.org/2001/XMLSchema#string

P2860

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Cancer statistics, 2005

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Antitumor activity of thalidomide in refractory multiple myeloma.

Mechanism of action in thalidomide teratogenesis.

Multiple myeloma.

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.

Thalidomide: a review of approved and investigational uses.

P304

99-109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19707399

http://www.w3.org/2001/XMLSchema#string

P932

2726063

http://www.w3.org/2001/XMLSchema#string